¶ Substantia Nigra
¶ Introduction
Substantia Nigra is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
¶ Overview
The substantia nigra (Latin for "black substance") is a midbrain structure that plays a critical role in motor control, reward processing, and cognitive function. Its distinctive dark appearance results from high concentrations of neuromelanin, a pigment that accumulates in [dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- with age (Zecca et al., 2003). The substantia nigra is one of the most prominently affected [brain regions/brain-regions) in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, where progressive loss of its [dopaminergic neurons[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc--TEMP--/cell-types)--FIX-- leads to the characteristic motor symptoms of the disorder (Damier et al., 1999).
¶ Anatomy and Organization
¶ Location and Gross Structure
The substantia nigra is located in the ventral midbrain, dorsal to the cerebral peduncles and ventral to the [red nucleus[/cell-types/[red-nucleus-expanded[/cell-types/[red-nucleus-expanded[/cell-types/[red-nucleus-expanded[/cell-types/[red-nucleus-expanded--TEMP--/cell-types)--FIX-- (Lanciego et al., 2012). It is a paired structure, with one substantia nigra on each side of the midline. The substantia nigra extends from the upper [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX-- through the midbrain and is part of the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- circuit, though it lies anatomically outside the basal ganglia proper.
¶ Pars Compacta (SNc)
The dorsal tier of the substantia nigra, the pars compacta, contains densely packed, neuromelanin-pigmented [dopaminergic neurons[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc--TEMP--/cell-types)--FIX-- that are the principal source of [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- for the dorsal [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX-- ([caudate nucleus[/cell-types/[caudate-nucleus[/cell-types/[caudate-nucleus[/cell-types/[caudate-nucleus[/cell-types/[caudate-nucleus--TEMP--/cell-types)--FIX-- and putamen) (Björklund & Dunnett, 2007). The SNc is estimated to contain approximately 400,000–600,000 dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in each hemisphere in healthy individuals (Pakkenberg et al., 1991). These [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- project through the nigrostriatal pathway — the mesostriatal dopaminergic system — which is essential for the initiation and modulation of voluntary movement.
SNc dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are characterized by:
- Expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis
- Accumulation of neuromelanin pigment (visible as the dark band on gross examination)
- Extensive axonal arbors — a single SNc neuron can form 100,000–250,000 synaptic connections in the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX-- (Matsuda et al., 2009)
- Autonomous pacemaker activity, driven by L-type calcium channels
¶ Pars Reticulata (SNr)
The ventral tier, the pars reticulata, contains primarily GABAergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- that constitute one of the two major output nuclei of the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- (the other being the [globus pallidus[/brain-regions/[globus-pallidus[/brain-regions/[globus-pallidus[/brain-regions/[globus-pallidus[/brain-regions/[globus-pallidus--TEMP--/brain-regions)--FIX-- interna) (Deniau et al., 2007). SNr [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are tonically active, firing at rates of 60–90 Hz, and exert continuous inhibition on their targets in the [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--, [superior colliculus[/brain-regions/[superior-colliculus[/brain-regions/[superior-colliculus[/brain-regions/[superior-colliculus[/brain-regions/[superior-colliculus--TEMP--/brain-regions)--FIX--, and [pedunculopontine nucleus[/brain-regions/[pedunculopontine-nucleus[/brain-regions/[pedunculopontine-nucleus[/brain-regions/[pedunculopontine-nucleus[/brain-regions/[pedunculopontine-nucleus--TEMP--/brain-regions)--FIX--.
The SNr receives GABAergic input from the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX-- via the direct pathway (striatonigral projection). When striatal medium spiny [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are activated by cortical input and dopaminergic facilitation, they inhibit the SNr, which in turn disinhibits thalamic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- — allowing movement to proceed. Disruption of this circuit underlies the motor symptoms of [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--.
¶ Pars Lateralis
A third, less well-defined region — the pars lateralis — has been identified in some classifications. It contains a mixed population of [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and is thought to contribute to non-motor (limbic and associative) functions (Halliday, 2004).
¶ Neurochemistry and Dopamine Synthesis
¶ Dopamine Pathway
The substantia nigra pars compacta is the origin of the nigrostriatal dopamine pathway, which is the primary dopaminergic innervation of the dorsal [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--. [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- synthesis proceeds through the following steps:
- L-tyrosine is transported into the neuron
- Tyrosine hydroxylase (TH) converts tyrosine to L-DOPA (the rate-limiting step)
- Aromatic L-amino acid decarboxylase (AADC) converts L-DOPA to dopamine
- Dopamine is packaged into synaptic vesicles by the vesicular monoamine transporter 2 (VMAT2)
Released dopamine acts on two main receptor families in the striatum:
- D1 receptors (direct pathway): excitatory effect on striatonigral [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, facilitating movement
- D2 receptors (indirect pathway): inhibitory effect on striatopallidal [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, suppressing unwanted movements
This dual-pathway model explains why dopamine depletion in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- leads to both bradykinesia (reduced D1 stimulation) and rigidity (increased D2-pathway activity) (Gerfen & Surmeier, 2011).
¶ Neuromelanin
[Neuromelanin] is a dark, insoluble pigment that accumulates in dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- of the SNc throughout life. It is formed from the oxidation of excess cytoplasmic dopamine and related catecholamines (Zecca et al., 2003). Neuromelanin has dual roles:
- Neuroprotective: chelates iron and sequesters toxic metabolites
- Potentially neurotoxic: released neuromelanin from dying [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- activates [microglia[/[striatum[/[striatum[/[striatum[/[striatum[/[striatum[/[striatum[/[striatum[/striatum] | Striatopallidal (indirect) | [GABA[/entities/[gaba[/entities/[gaba[/entities/[gaba[/entities/[gaba--TEMP--/entities)--FIX-- |
| Subthalamic nucleus | Subthalamonigral | [glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate--TEMP--/entities)--FIX-- |
| [Cerebral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- | Corticonigral | [glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate--TEMP--/entities)--FIX-- |
| Pedunculopontine nucleus | Tegmentonigral | [acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine--TEMP--/entities)--FIX-- / Glutamate |
| Dorsal raphe nucleus | Raphenigral | [serotonin[/entities/[serotonin[/entities/[serotonin[/entities/[serotonin[/entities/[serotonin--TEMP--/entities)--FIX-- |
¶ Efferent Projections
- SNc → [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX-- (nigrostriatal): Dopaminergic; the major output of the pars compacta
- SNr → [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--: GABAergic; targets ventral anterior and ventrolateral nuclei
- SNr → Superior colliculus: GABAergic; controls saccadic eye movements
- SNr → Pedunculopontine nucleus: GABAergic; influences locomotion
¶ Role in Parkinson's Disease
¶ Neurodegeneration of SNc Dopaminergic Neurons
[Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- is pathologically defined by the progressive loss of [dopaminergic neurons[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc--TEMP--/cell-types)--FIX-- in the substantia nigra pars compacta. By the time motor symptoms appear, approximately 50–70% of SNc dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- have already been lost, and striatal dopamine levels are reduced by 60–80% (Kalia & Lang, 2015). The loss follows a characteristic ventrolateral-to-dorsomedial gradient within the SNc, with the ventrolateral tier (projecting to the dorsal putamen) being most severely affected (Damier et al., 1999).
¶ Lewy Body Pathology
Surviving SNc [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- frequently contain Lewy bodies — intracellular inclusions composed primarily of misfolded [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--] (Spillantini et al., 1997). Lewy bodies and Lewy neurites are pathological hallmarks of PD and are believed to represent a cellular response to [protein aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation--TEMP--/mechanisms)--FIX-- stress. The [prion-like spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading--TEMP--/mechanisms)--FIX-- hypothesis proposes that pathological [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- propagates through connected neural circuits in a stereotyped pattern, as described by Braak staging (Braak et al., 2003).
¶ Selective Vulnerability
The selective vulnerability of SNc dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- to degeneration in PD is a central question in the field (Surmeier et al., 2017). Several factors contribute to the vulnerability of these [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (see also [Selective Neuronal Vulnerability):
- High metabolic demand: SNc [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- have extremely large axonal arbors and autonomous pacemaking activity, resulting in basal oxygen consumption rates 3-fold higher than [ventral tegmental area[/brain-regions/[ventral-tegmental-area[/brain-regions/[ventral-tegmental-area[/brain-regions/[ventral-tegmental-area[/brain-regions/[ventral-tegmental-area--TEMP--/brain-regions)--FIX-- (VTA) dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (Pacelli et al., 2015)
- Calcium oscillations: Pacemaker activity relies on L-type Cav1.3 calcium channels, leading to sustained intracellular calcium influx and mitochondrial stress (Chan et al., 2007)
- Dopamine metabolism: Cytoplasmic dopamine generates [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- through auto-oxidation and enzymatic metabolism, contributing to [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--
- Iron accumulation: The substantia nigra has the highest iron concentration of any brain region, and iron levels increase with age, promoting [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- and oxidative damage (Dexter et al., 1989)
- Reduced trophic support: Decreased expression of [GDNF[/proteins/[gdnf[/proteins/[gdnf[/proteins/[gdnf[/proteins/[gdnf--TEMP--/proteins)--FIX-- and [BDNF[/proteins/[bdnf[/proteins/[bdnf[/proteins/[bdnf[/proteins/[bdnf--TEMP--/proteins)--FIX-- in the aging SNc
¶ Genetic Factors
Multiple [genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes implicated in familial [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- converge on pathways active in SNc [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--:
- [SNCA[/genes/[snca[/genes/[snca[/genes/[snca[/genes/[snca--TEMP--/genes)--FIX-- ([alpha-synuclein/proteins/alpha: Mutations or multiplications cause autosomal dominant PD with Lewy body pathology
- [LRRK2[/genes/[lrrk2[/genes/[lrrk2[/genes/[lrrk2[/genes/[lrrk2--TEMP--/genes)--FIX-- (LRRK2 kinase/proteins: Most common genetic cause of PD; regulates vesicle trafficking and [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--
- [PRKN[/genes/[prkn[/genes/[prkn[/genes/[prkn[/genes/[prkn--TEMP--/genes)--FIX-- ([Parkin[/proteins/[parkin[/proteins/[parkin[/proteins/[parkin[/proteins/[parkin--TEMP--/proteins)--FIX-- and [PINK1/proteins/pink1 ([PINK1[/proteins/[pink1[/proteins/[pink1[/proteins/[pink1[/proteins/[pink1--TEMP--/proteins)--FIX--: Autosomal recessive PD; critical for [mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy--TEMP--/mechanisms)--FIX-- and mitochondrial quality control
- [PARK7[/genes/[park7[/genes/[park7[/genes/[park7[/genes/[park7--TEMP--/genes)--FIX-- ([DJ-1): Oxidative stress sensor and mitochondrial protector
- [GBA1[/genes/[gba[/genes/[gba[/genes/[gba[/genes/[gba--TEMP--/genes)--FIX-- ([GCase[/proteins/[gba[/proteins/[gba[/proteins/[gba[/proteins/[gba--TEMP--/proteins)--FIX--: Lysosomal enzyme; mutations are the most common genetic risk factor for PD
¶ neuroinflammation in the Substantia Nigra
¶ Microglial Activation
The substantia nigra shows prominent [microglial/cell-types/microglia activation in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, as first demonstrated by McGeer et al. (1988) through HLA-DR immunostaining (McGeer et al., 1988). Activated [microglia in the SNc release pro-inflammatory mediators including:
- Tumor necrosis factor-alpha (TNF-α)
- Interleukin-1 beta (IL-1β) and interleukin-6 (IL-6)
- Reactive oxygen and nitrogen species
- Prostaglandins
This chronic [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- creates a feed-forward cycle: neuronal death releases neuromelanin and aggregated [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--, which further activate [microglia, amplifying the inflammatory response (Hirsch & Hunot, 2009).
¶ Astrocyte Dysfunction
[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--][astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--] in the substantia nigra undergo reactive changes in Parkinson's Disease, with increased [glial fibrillary acidic protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- ([GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- expression (Booth et al., 2017). Astrocytic dysfunction impairs:
- Glutamate buffering, contributing to excitotoxic stress
- Potassium homeostasis
- Metabolic support to dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- integrity
¶ Other Diseases Affecting the Substantia Nigra
Beyond [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, the substantia nigra is affected in several other conditions:
- [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--: SNc dopaminergic loss plus widespread cortical Lewy body pathology
- [multiple system atrophy[/diseases/[msa[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX--: SNc degeneration with glial cytoplasmic inclusions in [oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes--TEMP--/cell-types)--FIX--
- Progressive Supranuclear Palsy: Neuronal loss in the SNc with tau] pathology
- [corticobasal degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration--TEMP--/diseases)--FIX--: Variable SNc involvement with asymmetric tau] deposition
- [Neurodegeneration with brain iron accumulation (NBIA)[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation--TEMP--/diseases)--FIX--: Iron overload in the substantia nigra and globus pallidus
¶ Therapeutic Approaches Targeting the Substantia Nigra
¶ Pharmacological
- [Levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa--TEMP--/treatments)--FIX--: The gold standard for PD treatment; a dopamine precursor converted to dopamine in remaining SNc [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and striatal terminals
- [Dopamine agonists[/treatments/[dopamine-agonists[/treatments/[dopamine-agonists[/treatments/[dopamine-agonists[/treatments/[dopamine-agonists--TEMP--/treatments)--FIX--: Directly stimulate dopamine receptors in the striatum, bypassing the need for dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- MAO-B inhibitors: Reduce dopamine degradation, prolonging its action (see [MAO-B Inhibitors/treatments/mao-b
¶ Surgical and Neurostimulation
- [Deep brain stimulation (DBS)[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation--TEMP--/treatments)--FIX--: High-frequency stimulation of the [subthalamic nucleus[/cell-types/[subthalamic-nucleus[/cell-types/[subthalamic-nucleus[/cell-types/[subthalamic-nucleus[/cell-types/[subthalamic-nucleus--TEMP--/cell-types)--FIX-- or globus pallidus interna modulates basal ganglia output, alleviating motor symptoms (Limousin et al., 1998)
- [Focused ultrasound[/treatments/[focused-ultrasound[/treatments/[focused-ultrasound[/treatments/[focused-ultrasound[/treatments/[focused-ultrasound--TEMP--/treatments)--FIX--: Emerging non-invasive approach for targeted neuromodulation
¶ Neuroprotective and Restorative Strategies
- Neurotrophic factor delivery: [GDNF[/proteins/[gdnf[/proteins/[gdnf[/proteins/[gdnf[/proteins/[gdnf--TEMP--/proteins)--FIX-- and neurturin infusion to promote SNc neuron survival
- Cell replacement therapy: Transplantation of stem cell-derived dopaminergic neurons into the striatum (see [Stem Cell Therapy[/treatments/[stem-cell-therapy[/treatments/[stem-cell-therapy[/treatments/[stem-cell-therapy[/treatments/[stem-cell-therapy--TEMP--/treatments)--FIX--
- [Gene therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX--: AAV-mediated delivery of AADC, GDNF, or [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX---targeting constructs
- [alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX-- immunotherapy: Antibodies targeting aggregated [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- (see [Immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy--TEMP--/treatments)--FIX--
¶ Research Techniques
¶ Neuroimaging
- DaTSCAN (ioflupane SPECT): Visualizes dopamine transporter density in the striatum as a surrogate for SNc neuronal integrity
- Neuromelanin-sensitive MRI: Directly images neuromelanin-containing neurons in the substantia nigra, providing a non-invasive measure of SNc degeneration (Sulzer et al., 2018)
- Iron-sensitive MRI (QSM): Quantifies iron accumulation in the substantia nigra
¶ Single-Cell Genomics
Recent [single-cell RNA sequencing[/technologies/[single-cell-genomics[/technologies/[single-cell-genomics[/technologies/[single-cell-genomics[/technologies/[single-cell-genomics--TEMP--/technologies)--FIX-- studies have identified molecularly distinct dopaminergic subpopulations within the SNc. Kamath et al. (2022) identified a specific subpopulation expressing SOX6 and AGTR1 that is highly susceptible to neurodegeneration in PD and enriched for PD-associated GWAS risk genes (Kamath et al., 2022). Agarwal et al. (2024) further refined this [taxonomy[/[taxonomy[/[taxonomy[/[taxonomy[/[taxonomy[/[taxonomy[/[taxonomy[/[taxonomy[/taxonomy, identifying ten transcriptomically distinct neuron types in the human substantia nigra (Agarwal et al., 2024).
¶ See Also
- [Dopaminergic Neurons (SNpc)[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc[/cell-types/[dopaminergic-neurons-snpc--TEMP--/cell-types)--FIX--
- [alpha-synuclein (α-Syn)[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--
- [Deep Brain Stimulation (DBS)[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation--TEMP--/treatments)--FIX--
- [Levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa--TEMP--/treatments)--FIX--
¶ External Links
- Substantia Nigra — StatPearls (NCBI)
- Substantia Nigra — Wikipedia
- Cleveland Clinic — Substantia Nigra
- Allen Human Brain Atlas — Substantia Nigra
¶ Background
The study of Substantia Nigra has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ Brain Atlas Resources
- Allen Brain Atlas
- Allen Human Brain Atlas
- Allen Mouse Brain Atlas
- Allen Cell Type Atlas
- BrainSpan Developmental Transcriptome
¶ Visual Resources
¶ Substantia Nigra Anatomical Schematic
This schematic highlights the position and basic anatomy of the [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX--, a central node in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- pathophysiology.
Image attribution: [FrozenMan, Substantia nigra (CC BY-SA 4.0)(https://commons.wikimedia.org/wiki/File:Substantia_nigra.gif)
¶ Conclusion
The Substantia Nigra is a critical brain region in the pathophysiology of Parkinson's disease, containing the dopaminergic neurons of the SNpc that project to the striatum. The selective vulnerability of these neurons to alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation makes the Substantia Nigra a central focus of PD research and therapeutic development. Understanding the molecular mechanisms underlying nigral degeneration, including Lewy body pathology spreading from the locus coeruleus, continues to inform disease-modifying strategies. Cell replacement approaches, including dopamine neuron transplantation and stem cell therapies, aim to restore nigrostriatal circuitry in PD patients.
¶ Research Evidence
¶ RNA sequencing and eQTL discovery in human putamen and substantia nigra
Identified 19,156 significant eQTL signals genome-wide at FDR 5%, including 359 secondary eQTLs. eQTL discovery was not simply driven by number of features tested; rate of eQTL discovery was highest in unannotated intronic and intergenic regions. 50.6% of putamen and 50.4% of substantia nigra eQTLs replicated in microarray data; 39.3% putamen and 50.6% substantia nigra eQTLs replicated in GTEx data.
Model System: Human postmortem brain tissue (putamen and substantia nigra from 117 neurologically healthy individuals of European descent)
Statistical Significance: FDR < 5%
Sebastian Guelfi et al., (2020)
¶ eQTL replication in external datasets
Replication rates: GTEx putamen 19-53.3%, GTEx substantia nigra 50.6-62.0%; PsychENCODE 64.2%; CommonMind 54.2%; Lappalainen lymphoblastoid cell lines only 22.0% putamen and 24.2% substantia nigra. Higher replication in brain tissues than lymphoblastoid cells.
Model System: Human brain datasets (GTEx, PsychENCODE, CommonMind) and lymphoblastoid cell lines
Statistical Significance: FDR < 5% in both datasets
Sebastian Guelfi et al., (2020)
¶ Cell type specificity analysis using weighted gene co-expression network analysis (WGCNA)
75% of analysed genes confidently assigned to specific cell type. eQTL target expression features assigned to cell types: 41.5%. Significant enrichment of neuronal genes in non-standard eQTL classes: i-eQTLs (FDR p=1.20x10^-2 in putamen), e-eQTLs (FDR p=1.21x10^-7 in substantia nigra), ex-ex-eQTLs (FDR p=2.28x10^-5 in substantia nigra). Splicing eQTLs also enriched for oligodendrocyte and astrocyte genes.
Model System: Human putamen and substantia nigra
Statistical Significance: FDR-corrected Fisher's Exact p-values: i-eQTLs p=1.20x10^-2, e-eQTLs p=1.21x10^-7, ex-ex-eQTLs p=2.28x10^-5
Sebastian Guelfi et al., (2020)
¶ Allele-specific expression (ASE) discovery and validation
Analysed 252,742 valid heterozygous SNPs. 19,266 (7.62%) were significant ASEs at FDR 5%, covering 8,654 genes. 12,096 ASEs in putamen, 11,871 in substantia nigra. 67% of testable ASE signals validated in lymphoblastoid cell lines. Inconsistent ASE signals (not unidirectional in >=10 individuals) were only in known imprinted genes (1.96% on X chromosome).
Model System: Human putamen and substantia nigra (subset with whole-exome sequencing)
Statistical Significance: FDR < 5%
Sebastian Guelfi et al., (2020)
¶ Cell type specificity of ASE signals
ASE-containing genes highly enriched for neuronally expressed genes: putamen FDR p=9.97x10^-235, substantia nigra FDR p=3.05x10^-97. Also significant enrichments for oligodendrocyte, astrocyte, microglia, and endothelial gene sets. Strength of evidence for cellular specificity was striking for ASEs compared to eQTLs.
Model System: Human putamen and substantia nigra
Statistical Significance: Putamen: FDR p=9.97x10^-235; substantia nigra: FDR p=3.05x10^-97
Sebastian Guelfi et al., (2020)
¶ Disease relevance of ASEs - GWAS enrichment
Highly significant enrichment of GWAS risk loci among ASEs: schizophrenia p=7.49x10^-35, Parkinson's disease p=4.19x10^-7. Using LD score regression, Parkinson's disease heritability enrichment appeared more specific to ASEs in substantia nigra. No enrichment in PD or schizophrenia heritability among eQTLs using same method.
Model System: ASE data overlapped with PD and schizophrenia GWAS
Statistical Significance: Schizophrenia: p=7.49x10^-35; Parkinson's disease: p=4.19x10^-7
Sebastian Guelfi et al., (2020)
¶ Dopaminergic neuron subtyping with classifier comparison to Kamath et al. dataset
Identified 14 TH+ subtypes (vs 10 in Kamath et al.). Found 7 new TH+ subtypes including SOX6 LPL subtype in substantia nigra and 4 CALB1+ subtypes in periaqueductal grey and VTA. Identified third class of TH+ neurons co-expressing GABAergic markers (CALCR and EBF2 clusters).
Model System: Human midbrain dopaminergic neurons from this study vs published dataset
Statistical Significance: Cross-validation performed with varying parameters
¶ Head-to-head comparison of tau PET tracers
Off-target binding profiles vary across tracers. 18F-flortaucipir shows off-target binding in basal ganglia, substantia nigra, longitudinal sinuses, pituitary, choroid plexus. 18F-RO948 and 18F-MK6240 show greater binding to meninges and skull. 18F-PI2620 shows promise for 4R tauopathies with lower off-target binding in basal ganglia.
Model System: Human participants
Statistical Significance: Not specified
¶ 18F-T807/AV-1451 evaluation in non-AD tauopathies
Regional tau PET patterns agreed with regions underlying clinical symptoms in atypical AD. FDG PET abnormally low where tau high. In PPA, tau signal spreading through language networks. In PSP, positive signals in substantia nigra, globus pallidus, and subthalamic nucleus, but some overlap with controls limiting early-stage detection.
Model System: PSP patients, primary progressive aphasia patients, atypical AD patients
Statistical Significance: p < 0.001 uncorrected for PSP vs controls in specific brain regions
Hartmuth C. Kolb, José Ignacio Andrés (2017)
¶ References
- Zecca L, Zucca FA, Albertini A, Rizzio E, Fariello RG. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's Disease. Neurology. 2006;67(7 Suppl 2]:S8-S11. https://pubmed.ncbi.nlm.nih.gov/14556719/
- Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's Disease. Brain. 1999;122(Pt 8]:1437-1448. https://pubmed.ncbi.nlm.nih.gov/10328523/
- Lanciego JL, Luquin N, Obeso JA. Functional neuroanatomy of the basal ganglia. Cold Spring Harb Perspect Med. 2012;2(12]:a009621. https://pubmed.ncbi.nlm.nih.gov/23226120/
- Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30(5]:194-202. https://pubmed.ncbi.nlm.nih.gov/17686545/
- Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's Disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry. 1991;54(1]:30-33. https://pubmed.ncbi.nlm.nih.gov/1905998/
- Matsuda W, Furuta T, Nakamura KC, et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci. 2009;29(2]:444-453. https://pubmed.ncbi.nlm.nih.gov/19776764/
- Deniau JM, Mailly P, Maurice N, Charpier S. The pars reticulata of the substantia nigra: a window to basal ganglia output. Prog Brain Res. 2007;160:151-172. https://pubmed.ncbi.nlm.nih.gov/17512935/
- Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci. 2011;34:441-466. https://pubmed.ncbi.nlm.nih.gov/21756978/
- Zhang W, Phillips K, Wielgus AR, et al. Neuromelanin activates [microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's Disease. Neurotox Res. 2011;19(1]:63-72.]https://pubmed.ncbi.nlm.nih.gov/21282661/
- Kalia LV, Lang AE. Parkinson's Disease. Lancet. 2015;386(9996]:896-912. https://pubmed.ncbi.nlm.nih.gov/26293853/
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. alpha-synuclein in Lewy bodies. Nature. 1997;388(6645]:839-840. https://pubmed.ncbi.nlm.nih.gov/9278044/
- Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's Disease. Neurobiol Aging. 2003;24(2]:197-211. https://pubmed.ncbi.nlm.nih.gov/12498954/
- Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18(2]:101-113. https://pubmed.ncbi.nlm.nih.gov/28257690/
- Pacelli C, Giguère N, Bhose MJ, et al. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr Biol. 2015;25(18]:2349-2360. https://pubmed.ncbi.nlm.nih.gov/26607649/
- Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's Disease. Nature. 2007;447(7148]:1081-1086. https://pubmed.ncbi.nlm.nih.gov/17460038/
- Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's Disease. J Neurochem. 1989;52(6]:1830-1836. https://pubmed.ncbi.nlm.nih.gov/2526771/
- McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive [microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's Disease brains. Neurology. 1988;38(8]:1285-1291.https://pubmed.ncbi.nlm.nih.gov/3399080/
- Hirsch EC, Hunot S. neuroinflammation in Parkinson's Disease: a target for [neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection--TEMP--/treatments)--FIX--]? Lancet Neurol. 2009;8(4]:382-397. https://pubmed.ncbi.nlm.nih.gov/19296920/
- Booth HDE, Hirst WD, Wade-Martins R. The role of astrocyte dysfunction in Parkinson's Disease pathogenesis. Trends Neurosci. 2017;40(6]:358-370. https://pubmed.ncbi.nlm.nih.gov/28495345/
- Sulzer D, Cassidy C, Horga G, et al. Neuromelanin detection by magnetic resonance imaging (MRI] and its promise as a biomarker for Parkinson's Disease. NPJ Parkinsons Dis. 2018;4:11. https://pubmed.ncbi.nlm.nih.gov/29203312/
- Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's Disease. N Engl J Med. 1998;339(16]:1105-1111. https://pubmed.ncbi.nlm.nih.gov/9421340/
- Kamath T, Abdulraouf A, Burber SJ, et al. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's Disease. Nat Neurosci. 2022;25(5]:588-595. https://pubmed.ncbi.nlm.nih.gov/35513515/
- Agarwal D, Sandor C, Volpato V, et al. Molecular profiling of human substantia nigra identifies diverse neuron types associated with vulnerability in Parkinson's Disease. Sci Adv. 2024;10(2]:eadi8287. https://doi.org/10.1126/sciadv.adi8287